GRAMD2A

Across TCGA pan-cancer cohorts, GRAMD2A RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of GRAMD2A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where GRAMD2A RNA is repressed in tumor relative to normal tissue. In most cancer types GRAMD2A is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and KICH are the cancer types where GRAMD2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GRAMD2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−2.377	<.001	11	view →
KIRC	Female	II,III,IV	−1.009	<.001	11	view →
KICH	Male	All	−2.062	<.001	10	view →
COAD	Female	II,III,IV	+0.890	<.001	10	view →
LUAD	Male	III,IV	−2.614	<.001	9	view →
LUSC	Female	II,III,IV	−3.380	<.001	6	view →
BRCA	Female	II,III,IV	−1.055	<.001	6	view →
KIRP	All	All	−0.739	<.001	5	view →
PAAD	All	All	+1.040	<.001	4	view →
STAD	All	All	+0.523	.012	4	view →
BLCA	All	All	+0.448	.037	4	view →
READ	Female	All	+1.557	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

GRAMD2A–THCA

Open the THCA breakdown →